BeOne Medicines reports new Phase 1 results across three liver and lung cancer programmes
BeOne reports new liver and lung cancer responses across three Phase 1 drugs, but dosing, safety and confirmatory evidence will shape development.
Pharma & Biotech
Pharma & Biotech
CatalYm’s visugromab lifted bladder cancer complete responses to 33%, but can it help patients avoid surgery?
CatalYm's visugromab lifted bladder cancer complete responses to 33% versus 8% with nivolumab alone. Can larger trials establish lasting benefit?
Pharma & Biotech
Genmab and Incyte are combining three attacks on KRAS-mutant colorectal cancer, but can they overcome EGFR resistance?
Genmab and Incyte will test petosemtamab with a KRAS G12D inhibitor in metastatic colorectal cancer. Can dual pathway targeting overcome resistance?
Pharma & Biotech
Bayer reports 58% lower metastasis or death risk with NUBEQA in Phase 3 prostate cancer trial
Bayer's NUBEQA improved four-year metastasis-free survival to 95% in high-risk prostate cancer. Overall survival evidence remains immature.
Pharma & Biotech
AstraZeneca’s bladder cancer combination cut death risk by 42%, but can it compete with an approved rival regimen?
AstraZeneca's VOLGA trial shows 42% lower death risk with IMFINZI and enfortumab vedotin. Can the regimen compete with approved bladder cancer therapy?
Pharma & Biotech
Pfizer’s new vaccine targets 25 pneumococcal serotypes, but can it outperform PREVNAR 20?
Pfizer's 25-valent pediatric vaccine shows strong Phase 2 immune responses, including against serotype 3. Can Phase 3 establish broader protection?
Pharma & Biotech
Genmab’s Rina-S slashed progression risk by 71%, but can it challenge ovarian cancer treatment standards?
Genmab's Rina-S cut progression risk by 71% and showed an overall survival benefit in Phase 3 ovarian cancer data. What remains before approval?
Pharma & Biotech
Palleon Pharmaceuticals reports rapid remissions with HLX79/E-602 in Phase 2 kidney disease trial
Palleon's HLX79/E-602 achieved remission in all seven high-dose patients by Week 36. Can the small Phase 2 kidney trial support larger studies?
Pharma & Biotech
Vopimetostat and daraxonrasib show strong tumor responses as Tango Therapeutics targets Phase 3
Tango Therapeutics reports 82% response with vopimetostat and daraxonrasib in pancreatic cancer. Explore the trial results and Phase 3 plans.
Pharma & Biotech
Rina-S Phase 3 success brings new hope for platinum-resistant ovarian cancer patients
Genmab's Rina-S cuts the death hazard by 57% in a Phase 3 ovarian cancer trial. Explore the survival results, treatment potential and FDA outlook.